- Biotechnology
- Healthcare
-
3.32
EPS
-
17.37
P/E
-
13B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
1801 AUGUSTINE CUT-OFF,WILMINGTON DE 19803,3024986700
CEO
Mr. Herve Hoppenot
Employess
2524
Sector
Healthcare
Industry
Biotechnology
Website
https://www.incyte.com
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Next Earnings Date
Oct. 29, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
-11.78%
Fiscal Year End
12-31
IPO Date
1993-11-04
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 26.40% | 14.45% | 11.49% | 8.87% |
| EPS | 21.07% | 38.71% | 58.25% | 74.51% |
| Equity | 39.98% | 21.93% | 25.73% | 18.76% |
| Cash | 21.16% | 22.52% | 28.54% | 8.88% |
| Return On Capital (ROIC) | 4.68% | 8.95% | 14.16% | 8.50% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 9.12 | 11.4 | 13.2 | 15 | 28.3 |
| Long Term Debt | 29.2 | 33.3 | 34.3 | 34.9 | 50.9 |
| LT Finance Leases | 38.3 | 33.3 | 34.3 | 34.9 | 32.6 |
| Shares Outstanding | 224 | 222 | 220 | 218 | 215 |
| Market Cap | 14,000 | 17,800 | 16,200 | 19,000 | 18,800 |
Price
News
3 Highly Rated Biotech Stocks for Your July Buy List
2 monthsThe healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are pushing the boundaries of medicine and transforming patient care.
investorplace.com
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
3 monthsTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
benzinga.com
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
3 monthsEvery investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
investorplace.com
Incyte: The Worst Has Been Avoided
3 monthsIn recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
seekingalpha.com
Incyte Announces Final Results of Tender Offer
3 monthsWILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
businesswire.com
Incyte Announces Preliminary Results of Tender Offer
3 monthsWILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
businesswire.com
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 monthsWILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
businesswire.com
Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions
3 monthsDublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
globenewswire.com
Incyte Completes Acquisition of Escient Pharmaceuticals
4 monthsWILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Escient Pharmaceuticals.
businesswire.com
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
4 monthsIncyte (INCY) reported earnings 30 days ago. What's next for the stock?
zacks.com
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
4 monthsWILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
businesswire.com
Incyte to Present at Upcoming Investor Conference
4 monthsWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Thro.
businesswire.com